Research programme: personalised cancer vaccines - Caperna

Alternative Names: NCI-4650

Latest Information Update: 22 Sep 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Moderna Therapeutics
Developer Caperna
Class Cancer vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer

Most Recent Events

11 Apr 2018 National Cancer Institute plans a phase I/II trial for Urogenital cancer, Gastrointestinal cancer, Malignant melanoma (Metastatic disease, second line therapy or greater) in USA, in April 2018 (NCT03480152)
22 Sep 2017 Moderna Therapeutics plans a phase I/II trial for Cancer in USA
22 Oct 2015 Preclinical trials in Cancer in USA (Parenteral)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.